(Arrhythmia, atherosclerosis, CHF)
Heart disease is largely caused by diet, lifestyle, and nutrient imbalances. Certain viruses and inflammation can also damage the heart. Fortunately, heart disease is often reversible, even if you have already had surgery and are on medications. Heart disease is serious. It is best to work with an holistic physician who can help you discover the cause of the problem and make specific recommendations for correction. Never stop taking heart medication without the guidance of a physician!
DIET AND LIFESTYLE RECOMMENDATIONS
- Follow the Ten Rules of Good Health
- Practice stress reduction techniques and anger management. People with “hot tempers” are at higher risk for cardiac events.
- Do NOT SMOKE! Smoking is one of the most damaging habits to the heart and cardiovascular system.
- Maintain a normal body weight.
- Exercise regularly. Be sure to consult your doctor if you are over 30, highly deconditioned, or have already-established heart disease. He/she can tell you how much exercise is safe for you to begin with.
PRIMARY SUPPORT
- Maxi Multi: 3 caps, 3 times per day with meals. This daily “multiple” contains high potency antioxidants. Optimal (not minimal) doses of antioxidants (ACES), magnesium, B complex vitamins, and bioflavonoids are particularly important for the heart. Take additional B complex vitamins if your multiple does not contain optimal doses. B vitamins, (especially B6, B12, and folic acid) lower homocysteine levels, an independent risk for heart disease that many researchers feel is more important than cholesterol levels.
- Max EPA (fish oil): 1-2 caps, 3 times per day with meals to prevent or reverse inflammation. Take higher doses as directed if your hs-CRP tests are elevated. Flax oil is also beneficial but requires a biochemical conversion in the body, which is deficient in many people, so fish oil is more certain.
- CoQ10: 50-300mg per day. This powerful antioxidant, produced by the body, diminishes with age. It is especially valuable for all types of heart disease. CHOLESTEROL-LOWERING DRUGS deplete CoQ10. (Amounts will depend on the severity of the disease. Lower doses may be used for health maintenance; higher doses in cases of arrhythmia, angina, and atherosclerosis).
- Magnesium: 2 taps, 3 times per day with meals (Target dose: 500-1500mg per day. Maxi Multi contains 500mg).
- Grape Seed Extract: 1 cap, 3 times per day with meals. (Target dose: 150-300mg daily). Proanthocyanidins in grape seed extract act as a potent antioxidants and ACE inhibitors. They also help prevent platelet aggregation (blood cells sticking together) and protect blood vessels from damage.
ADDITIONAL SUPPORT
For High Blood Pressure
- Forskolin (Coleus forskohlii): 1-2 caps per day.
- See also HIGH BLOOD PRESSURE recommendations.
For Atherosclerosis
- See also ATHEROSCLEROSIS recommendations.
For Arrhythmia
- Low dose aspirin (81mg): 1 tab per day.
- L-carnitine: 500-1,000mg, 3 times per day with meals.
For Congestive Heart Failure
- L-carnitine: 500mg, 3 times per day with meals.
- Hawthorn Plus+: 2 caps, 2 times per day with meals.
CoQ10 and it’s use in CHF (Congestive Heart Failure):
http://www.ncbi.nlm.nih.gov/pubmed/19966871
“… Coenzyme Q10 (CoQ10) is essential for electron transport within the mitochondria and hence for ATP generation and cellular energy production. We recently demonstrated that plasma levels of CoQ10 are an independent predictor of survival in a cohort of 236 patients with chronic heart failure (CHF) followed for a median of 2.69 years. This is consistent with previous studies which have shown myocardial CoQ10 depletion in CHF, and correlated with the severity of the underlying disorder. Several intervention studies have been undertaken with CoQ10 in CHF, including randomized controlled trials with mostly positive outcomes in relation to improvement in plasma levels of CoQ10. A meta-analysis showed that CoQ10 resulted in an improvement in ejection fraction of 3.7% (95%CI 1.59-5.77) and the mean increase in cardiac output was 0.28 L/minute (95%CI 0.03-0.53). In a subgroup analysis, studies with patients not taking ACE inhibitors found a 6.7% increase in ejection fraction. The ongoing Q-SYMBIO trial will address whether CoQ10 supplementation improves survival in CHF patients. CoQ10 depletion may also be a contributory factor for why statin intervention has not improved outcomes in CHF. There is an emerging evidence base in support of CoQ10 as an adjunctive therapy in CHF.”
http://faculty.washington.edu/ely/coenzq10.html
“…The majority of the clinical studies concerned the treatment of heart disease and were remarkably consistent in their conclusions: that treatment with CoQ10 significantly improved heart muscle function while producing no adverse effects or drug interactions. …”
Dr. Myatt’s Conclusion:
CoQ10 is beneficial for nearly every type of Heart Disease (angina, arrhythmia, atherosclerosis, cardiomyopathy, heart failure, congestive heart failure, myocardial infarction (1-18)
Maxi Marine O3 (Fish Oil) and it’s use in CHF (Congestive Heart Failure):
http://www.ncbi.nlm.nih.gov/pubmed/8733172
“…Fish oil may decrease cardiac afterload by an antivasopressor action and by reducing blood viscosity, may reduce arrhythmic risk despite supporting the heart’s beta-adrenergic responsiveness, may decrease fibrotic cardiac remodeling by impeding the action of angiotensin II and, in patients with coronary disease, may reduce the risk of atherothrombotic ischemic complications. Since the measures recommended here are nutritional and carry little if any toxic risk, there is no reason why their joint application should not be studied as a comprehensive nutritional therapy for congestive heart failure. …”
References
1.) Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-9.
2.) Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, Vered Y, Vidne BA, Aravot D. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004 May;27(5):295-9.
3.) Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002 Nov;56(11):1137-42.
4.) Kumar A, Kaur H, Devi P, Mohan V. Role of Coenzyme Q10 (CoQ10) in Cardiac disease, Hypertension and Meniere- like syndrome. Pharmacol Ther. 2009 Jul 25. [Epub ahead of print]
5.) Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990;12(3):163-8.
6.) Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988 Jul 1;66(13):583-90.
7.) Langsjoen P, Langsjoen A, Willis R, and Folkers K. The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. Anti-Aging Medical Therapeutics. Klatz RM and Goldman R (eds.). Health Quest Publications. 1997;113-120.
8.) Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18(S):s145-s151.
9.) Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4240-4.
10.) Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atheroscler Thromb. 2005;12(2):111-9.
11.) Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008 Oct 28;52(18):1435-41.
12.) Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of “Q-symbio”–a multinational trial. Biofactors. 2003;18(1-4):79-89.
13.) Mortensen S.A., Vadhanavikit S., Muratsu K., Folkers K. (1990) Coenzyme Q10: Clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. In: Int. J. Tissue React., Vol. 12 (3), pp 155-162.
14.) Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension, and heart failure. Biofactors. 2003;18(1-4):91-100.
15.) Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004 Nov 15;94(10):1306-10.
16.) Singh RB; Wander GS et al Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther, 12(4):347-53 1998 Sep.
17.) Singh RB; Wander GS et al Cardiovasc Drugs Ther, 12(4):347-53 1998 Sep.
18.) Weant KA, Smith KM. The role of coenzyme Q10 in heart failure. Ann Pharmacother. 2005;39(9):1522-6.